Drugs / PfAMA-1-FVO[25-545]
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00431808 | May 2007 → Jun 2008 | malaria | African Malaria Network Trust | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00730782 Comparator | Nov 2005 → Sep 2007 | Plasmodium falciparum malaria | European Vaccine Initiative | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PfAMA-1-FVO[25-545] | “The malaria vaccine, PfAMA1-FVO [25-545] is a recombinant protein Pichia pastoris-expressed AMA-1 from Plasmodium falciparum FVO clone adsorbed to Alhydrogel(®), the control...” PMID 27577237 ↗ Aug 2016 |
| Known as | PfAMA1 | “The experimental vaccine PfAMA1 formulated in Alhydrogel” NCT00730782 ↗ |
| Modality | Vaccine | “The malaria vaccine, PfAMA1-FVO [25-545] is a recombinant protein” PMID 27577237 ↗ Aug 2016 |
| Route | Subcutaneous | “Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1” NCT00730782 ↗ |